Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

Lori M Laffel; Thomas Danne; Georgeanna J Klingensmith; William V Tamborlane; Steven Willi; Philip Zeitler; Dietmar Neubacher; Jan Marquard; Tatiana Bardymova; Margarita Barrientos Perez; Kathleen Bethin; Petter Bjornstad; Irina Bondar; Mimi Chen; Jin-Ho Choi; Mark A Clements; Javier Ricardo Colomar; Mark Daniels; Chaicharn Deerochanawong; Vivek S Desai; Jean-Claude G Desmangles; Robert G Dillon; Naznin M Dixit; Hongwei Du; Rachel Edelen; Diego Espinoza Peralta; María Verónica Felipe Gacioppo; Tania Maria Bulcão Lousada Ferraz; Galina Galkina; Mary Patricia Gallagher; Minu George; Edgar Gonzalez; Michael Everett Gottschalk; Giancarlo Guido; Amir Ali Hassan; Eli Hershkovitz; Lina P Huerta-Saenz; Jin Soon Hwang; Jaime Orlando Ibarra Gomez; Lydia Irizarry Gonzalez; Nina Jain; David H Jelley; Ho-Seong Kim; Tatiana Kovalenko; Lori Michelle B Laffel; Steven B Leichter; Raphael Del Roio Liberatore Jr; Jane Lynch; Farid Hussain Mahmud; Oleg Arturovich Malievskiy; Andrew Muir; Bryce A Nelson; Luis Alejandro Nevarez Ruiz; Micah L Olson; Emilia Susana Pelayo Orozco; Valentina Peterkova; Fernando Ramón Ramírez Mendoza; Konda Mohan Reddy; Henry Rodriguez; Javier Andres Saenz; Julia Samoilova; Karl-Otfried Schwab; Sejal H Shah; Naim Shehadeh; Ashley H Shoemaker; Yulia Skorodok; Aleksandr Sobolev; Silvana Ernestina Solís; Shylaja Srinivasan; William V Tamborlane; Eva Tsalikian; Farida Valeeva; Carl D Vance; Pedro A Velasquez-Mieyer; Rafael Margarito Violante Ortiz; Olga Votyakova; Haiyan Wei; Ruth S Weinstock; Mark D Wheeler; Brandy Alexandra Wicklow; Steven M Willi; Kupper A Wintergerst; Risa M Wolf; Jamie Ruth Wood; Chandan Yaliwal; Hernán Yupanqui Lozno

doi:10.1016/S2213-8587(22)00387-4

Latest

Efficacy and security of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in younger individuals with sort 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, section 3 trial

Editor2

-

February 2, 2023

0

[ad_1]

Efficacy and security of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in younger individuals with sort 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, section 3 trial – The Lancet Diabetes & Endocrinology

[adinserter block=”4″]

[ad_2]

Source link

LEAVE A REPLY Cancel reply